awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34359274-E436016A-2F83-49F3-BD2C-7F89FBF9A550
Q34359274-E436016A-2F83-49F3-BD2C-7F89FBF9A550
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34359274-E436016A-2F83-49F3-BD2C-7F89FBF9A550
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
P2860
Q34359274-E436016A-2F83-49F3-BD2C-7F89FBF9A550
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34359274-E436016A-2F83-49F3-BD2C-7F89FBF9A550
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0ba405fb77fa87654e23e7014e11ad563ddd08a0
P2860
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.